Fig. 7.

CD147 is an immunomodulatory target for hepatocellular carcinoma therapy. 106 Hepa16 cells were injected into the liver of WT and CD147^T-KO C57BL/6 mice in situ. Starting at day 3, the WT mice were treated with 10 mg/kg of CD147 antibody by intravenous tail vain injection, every 3 days for 2 weeks total. Six mice in the control group, six mice in the CD147^T-KO group and five mice in the antibody treatment group, one mouse death due to anesthesia. A. Small animal imaging analysis was used to measure the growth of the tumor at days 3, 7, 14, 28 and 42. B. Hematoxylin-eosin staining was used to analyze tumor growth at day 14. All image analysis is shown at 100 × magnification. C. Analysis of the ratio of liver to body weight percentages at day 14 of all treatment groups. D–E. Flow cytometry analysis of NK cells in the thymus (D) and liver (E) after injection of Hepa16 cells.